UBS lowered the firm’s price target on Keurig Dr Pepper to $36 from $38 and keeps a Buy rating on the shares ahead of the Q4 earnings report on February 22. The set up heading into the report remains “tricky,” but thinks concerns on weaker organic growth are reflected in valuation and the risk/reward skews to the upside, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KDP:
- KDP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Keurig Dr Pepper Announces Upcoming Quarterly Dividend
- Keurig Dr Pepper Declares Quarterly Dividend
- Keurig Dr Pepper expands partnership with Italian coffee company Lavazza
- Keurig Dr Pepper price target raised to $37 from $36 at Barclays